Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics (SLN) reported its Q1 2025 financial results and business updates. The company ended Q1 with $136.5 million in cash and investments, down from $147.3 million in Q4 2024. Net loss widened to $28.5 million ($0.20 per share) compared to $2.3 million ($0.02 per share) in Q1 2024. R&D expenses increased by $9.0 million to $20.8 million, while G&A expenses rose by $1.0 million to $7.7 million. The company is implementing cost-saving measures to extend its cash runway into 2028. Key developments include advancing the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), with enrollment completion expected by end-2025. Additional Phase 1 results will be presented at EHA 2025. The company is also progressing with Phase 3 readiness activities for zerlasiran in cardiovascular disease.

Silence Therapeutics (NASDAQ: SLN), a clinical-stage company developing siRNA therapies, has appointed Tim McInerney to its Board of Directors. McInerney brings over 30 years of pharmaceutical and biotechnology experience, including significant roles in early-stage financings of companies like Cougar Biotech and Kite Pharma. He previously served as chairman of Insite Vision and led the Special Committee in Emisphere Technologies' $1.8 billion sale to Novo Nordisk.

The company also announced that James Ede-Golightly will retire from the Board at the June 2025 AGM after serving since 2019. Ede-Golightly played a crucial role in Silence's evolution, including its delisting from the London Stock Exchange and transition to becoming a Nasdaq-listed U.S. domestic issuer.

Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company specializing in siRNA therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company's management will deliver a corporate overview presentation on Wednesday, March 12th at 1:00 p.m. ET.

Interested parties can access the live webcast through the Investors section of Silence's website at www.silence-therapeutics.com. A recorded version of the presentation will be made available for later viewing after the conference concludes.

Silence Therapeutics (SLN) reported its full year 2024 financial results, ending with $147.3 million in cash and investments. The company's collaboration revenue increased to $43.1 million from $30.9 million in 2023, while net loss improved to $45.3 million ($0.33 per share) from $54.2 million in 2023.

Key developments include: positive regulatory feedback for zerlasiran's Phase 3 study design, though initiation depends on securing a partnership; anticipated full enrollment in divesiran's SANRECO Phase 2 study for PV by end of 2025; and planned Phase 1 studies for SLN548 in H2 2025. R&D expenses increased to $67.9 million from $56.9 million, while G&A expenses slightly rose to $26.9 million.

The company has extended its cash guidance into 2027, focusing on rare condition treatments where they can deliver first-in-class and/or best-in-class siRNAs.

Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company focused on developing siRNA therapies, has scheduled its fourth quarter and full year 2024 financial results release for February 27, 2025. The company will host a conference call and webcast at 8:00 a.m. ET / 1:00 p.m. GMT on the same day, where management will discuss financial results and provide a business update. The webcast will be accessible through the Investors section of Silence's website and will remain archived for future reference.

Silence Therapeutics presented additional Phase 1 results for divesiran in polycythemia vera (PV) patients at the ASH Annual Meeting. The SANRECO study data showed substantial reduction in phlebotomy frequency and lower hematocrit levels in 19 PV patients. Following treatment, only five phlebotomies were required during the 18-week treatment period, compared to 79 phlebotomies before enrollment.

The company also announced dosing of the first subject in the Phase 2 portion of the SANRECO study. Divesiran demonstrated sustained hematocrit reduction, favorable effects on iron metabolism, and consistent target engagement through increased hepcidin levels. The treatment has been well-tolerated with no dose-limiting toxicities.

Silence Therapeutics (Nasdaq: SLN), a global clinical stage biotechnology company focused on developing precision engineered medicines for disease treatment, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4th at 10:00 a.m. ET. Interested parties can access the live webcast through the Investors section of Silence's website, with an archived replay available after the conference.

Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, showing significant results in treating high lipoprotein(a) levels in ASCVD patients. The study demonstrated >80% mean time-averaged placebo-adjusted Lp(a) reductions over 36 weeks, with maximum reductions exceeding 90%. The treatment, administered at various doses and intervals, showed persistent effects up to 60 weeks after initial dosing with no safety concerns. The data was presented at the AHA Scientific Sessions 2024 and published in JAMA, marking the first study to report time-averaged Lp(a) analyses.

Silence Therapeutics (SLN) reported its Q3 2024 financial results with cash position of £129.0 million ($172.7 million) as of September 30, 2024. The company's collaboration revenue decreased to £1.1 million in Q3 2024 from £2.7 million in Q3 2023. R&D expenses increased to £15.3 million from £8.9 million year-over-year, while G&A expenses rose to £5.6 million from £5.0 million. Net loss widened to £27.0 million from £8.2 million in Q3 2023.

The company will present results from the ALPACAR-360 Phase 2 study of zerlasiran at AHA and Phase 1 results of divesiran at ASH in December 2024. Starting January 2025, SLN will be classified as a 'large accelerated filer' by SEC.